Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

AAAbio Introduces High-Specificity Anti-MYCT1 Antibody to Advance Cancer and Gene Regulation Research


News provided by

AAA Biotech

May 05, 2026, 09:06 ET

Share this article

Share toX

Share this article

Share toX

AAAbio has launched a highly specific anti-MYCT1 antibody to support cancer and gene regulation research. Designed for techniques such as Western blot, ELISA, and flow cytometry, it provides reliable detection of MYCT1, a key MYC pathway protein. With affinity purification and a ready-to-use format, the reagent improves accuracy, reproducibility, and workflow efficiency in molecular biology and oncology studies.

LA JOLLA, Calif., May 5, 2026 /PRNewswire-PRWeb/ -- AAAbio has announced the availability of its anti-MYCT1 antibody, a research-grade tool designed to support scientists investigating gene regulation, tumor biology, and cellular proliferation pathways.

MYCT1 (MYC target 1) has increasingly attracted attention in oncology research due to its association with MYC-driven transcriptional activity. MYC is one of the most studied oncogenes, and downstream targets like MYCT1 are critical for understanding tumor progression and cellular signaling mechanisms. However, consistent detection of MYCT1 protein expression has remained technically challenging due to variability in antibody specificity and assay compatibility.

AAAbio's anti-MYCT1 antibody addresses this gap by offering a validated reagent suitable for multiple laboratory techniques, including Western blot, ELISA, and flow cytometry. This multi-application flexibility allows both research scientists and lab assistants to integrate the antibody seamlessly into existing workflows without needing multiple reagents.

The antibody is produced using affinity purification methods, a process widely recognized for enhancing specificity and reducing background noise in protein detection assays. This is particularly relevant for MYCT1, where precise detection is essential for distinguishing subtle expression changes in cancer models.

For lab assistants handling routine assays, the product is supplied in a ready-to-use liquid format, minimizing preparation time and reducing procedural variability. This operational simplicity is not trivial—small inconsistencies in reagent handling often lead to reproducibility issues across experiments.

From a research perspective, MYCT1 is implicated in regulating cell cycle progression and apoptosis, making it a relevant biomarker candidate in studies involving tumor growth and therapeutic response. Reliable detection tools such as this antibody are therefore critical for producing reproducible and interpretable data.

AAAbio emphasizes that the antibody is intended strictly for research use only, aligning with industry standards for preclinical experimentation. This ensures that researchers maintain compliance while exploring MYCT1's biological roles.

The company has built its catalog around high-affinity polyclonal antibodies designed to support a wide range of experimental techniques, including immunohistochemistry and immunocytochemistry . This broader platform positions AAAbio as a supplier focused on versatility and application-driven design rather than single-use reagents.

For laboratories working in oncology, gene expression profiling, or molecular biology, the introduction of this anti-MYCT1 antibody provides a practical solution to a specific but important problem: reliable detection of a low-abundance regulatory protein.

If your lab is studying MYC pathways and you're still dealing with inconsistent MYCT1 signals, the problem is likely your reagent, not your protocol.

About the Company

AAA Biotech continues to expand its catalog of life science reagents, including ELISA kits, antibodies, proteins, and related assay solutions. By aligning product development with the evolving needs of researchers, the company supports laboratories seeking dependable tools for biomarker detection and biological analysis.

As research moves toward increasingly data-driven and targeted approaches, next-generation ELISA kits remain essential components of experimental success. Through continued innovation and validation, AAA Biotech is contributing to more accurate, reproducible, and impactful life science research.

For more information and queries:

Visit the company's official website: https://www.aaabiotech.com/.

Tel: +1 (619) 604-9440

Fax: +1 (619) 604-9441

Toll Free: +1-800-604-9114

Email: [email protected]

Tech Support: [email protected]

Media Contact

Cynthia Lee, AAA Biotech, 1 619-604-9440, [email protected], https://www.aaabiotech.com/

SOURCE AAA Biotech

Modal title

AAAbio Introduces High-Specificity Anti-MYCT1 Antibody to Advance Cancer and Gene Regulation Research
AAAbio Introduces High-Specificity Anti-MYCT1 Antibody to Advance Cancer and Gene Regulation Research
AAAbio Introduces High-Specificity Anti-MYCT1 Antibody to Advance Cancer and Gene Regulation Research

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.